Hodgkin Lymphoma Molecular Profiling & Clinical Outcomes in U.S. Community

Clinical Trial Summary

The purpose of this study is to gather data on patients diagnosed with and treated for classical Hodgkin Lymphoma (cHL). It aims to closely observe how treatment for cHL is rendered, as well as assess the outcome of those treatment options and their impact on quality of life. Additional analyses will also attempt to identify prognostic or predictive biomarkers

See also
Status	Clinical Trial	Phase
Completed	`NCT01665768` - Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma	Phase 2
Completed	`NCT01188798` - Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies	Phase 3
Completed	`NCT00975975` - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer	Phase 2
Completed	`NCT00606437` - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants	Phase 1
Completed	`NCT00150462` - Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies	Phase 1
Completed	`NCT01458288` - A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease	Phase 2
Completed	`NCT00990587` - Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy	Phase 1
Terminated	`NCT00594308` - In-Vivo Activated T-Cell Depletion to Prevent GVHD	N/A
Completed	`NCT00469729` - Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy	Phase 2/Phase 3
Completed	`NCT00552825` - Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children	N/A
Completed	`NCT00165438` - Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy	N/A
Terminated	`NCT00176930` - Stem Cell Transplant for Hematological Malignancy	N/A
Recruiting	`NCT02007811` - Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination	Phase 1/Phase 2
Completed	`NCT01221857` - Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies	Phase 1/Phase 2
Completed	`NCT00665314` - Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).	Phase 2
Completed	`NCT00569842` - Investigation of the Cylex® ImmuKnow® Assay	N/A
Completed	`NCT00284804` - A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease	Phase 2
Completed	`NCT00256191` - Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies	Phase 1
Completed	`NCT00396201` - AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease	Phase 2
Completed	`NCT00144677` - Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation	Phase 2

NCT number	NCT02856646
Study type	Observational
Source	Bristol-Myers Squibb
Contact
Status	Completed
Phase
Start date	October 7, 2016
Completion date	September 30, 2020

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms